Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 7/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9775205 | 0.86 | ACE (0.44) | ACEKMT2AMEN1USP2LMNA | |
| SCHEMBL10747717 | 0.85 | ACE (0.55) | ACEKMT2AMEN1USP2LMNA | |
| SCHEMBL5364563 | 0.85 | ACE (0.55) | ACEKMT2AMEN1USP2LMNA | |
| SCHEMBL5716228 | 0.85 | ACE (0.55) | ACEKMT2AMEN1USP2LMNA | |
| SCHEMBL5716232 | 0.85 | ACE (0.55) | ACEKMT2AMEN1USP2LMNA | |
| SCHEMBL9256682 | 0.85 | CTSL (0.54) | ACEKMT2AMEN1USP2LMNA | |
| SCHEMBL9592654 | 0.83 | CTSL (0.54) | ACEKMT2AMEN1USP2LMNA | |
| SCHEMBL9773233 | 0.83 | CTSL (0.54) | ACEKMT2AMEN1USP2LMNA | |
| SCHEMBL9775310 | 0.83 | ACE (0.53) | ACEKMT2AMEN1USP2LMNA | |
| SCHEMBL9175234 | 0.82 | ACE (0.60) | ACEKMT2AMEN1USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675827-B1 | NOVEL METHOD FOR PREPARATION OF CRYSTALLINE PERINDOPRIL ERBUMINE | SERVIER LAB (FR) | 2009-12-16 | — | — | EP | disclosed |
| US-7521566-B2 | Process for preparation of perindopril and salts thereof | LES LABORATOIRES SERVIER (FR) | 2009-04-21 | — | — | US | disclosed |
| US-7456296-B2 | Method for preparation of crystalline perindopril erbumine | LUPIN LTD (IN) | 2008-11-25 | — | — | US | disclosed |
| EP-1603558-B1 | PROCESS FOR PREPARATION OF PERINDOPRIL AND SALTS THEREOF | SERVIER S A LAB (FR) | 2008-05-21 | — | — | EP | disclosed |
| US-20070149604-A1 | Reacting perindopril in a solvent selected from N,N-dimethylformamide, dimethoxymethane, 2,2-dimethoxypropane and 1,2-dimethoxyethane with tert-butylamine, crystallization; stereospecific | LUPIN LTD. (IN) | 2007-06-28 | — | — | US | disclosed |
| WO-2006137082-A1 | PROCESS FOR INDUSTRIALLY VIABLE PREPARATION OF PERINDOPRIL ERBUMINE | POTLURI RAMESH BABU (IN) | 2006-12-28 | — | — | WO | disclosed |
| US-20060276659-A1 | Process for preparation of perindopril and salts thereof | LIPIN LIMITED (IN) | 2006-12-07 | — | — | US | disclosed |
| EP-1675827-A1 | NOVEL METHOD FOR PREPARATION OF CRYSTALLINE PERINDOPRIL ERBUMINE | Lupin Limited (IN) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005037788-A1 | NOVEL METHOD FOR PREPARATION OF CRYSTALLINE PERINDOPRIL ERBUMINE | LUPIN LTD. (IN) | 2005-04-28 | — | — | WO | disclosed |
| US-4644008-A | Perhydroindole-2-carboxylic acids as antihypertensives | ADIR (FR) | 1987-02-17 | — | — | US | disclosed |
| US-4616031-A | Perhydroindole-2-carboxylic acids as antihypertensives | ADIR (FR) | 1986-10-07 | — | — | US | disclosed |
| US-4616030-A | Perhydroindole-2-carboxylic acids as antihypertensives | ADIR (FR) | 1986-10-07 | — | — | US | disclosed |
| US-4616029-A | Perhydromdole-2-carboxylic acids as antihypertensives | ADIR (FR) | 1986-10-07 | — | — | US | disclosed |
| US-4565819-A | ENZYME INHIBITORS, HYPOTENSIVE AGENTS | ADIR (FR) | 1986-01-21 | — | — | US | disclosed |
| US-4508729-A | Substituted iminodiacids, their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1985-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276659-A1 | Process for preparation of perindopril and salts thereof | CYP2C9, DPYD, CYP2C8 | ACE 10/4885KMT2A 2501/4885MEN1 4541/4885 |
| US-20070149604-A1 | Reacting perindopril in a solvent selected from N,N-dimethylformamide, dimethoxymethane, 2,2-dimethoxypropane and 1,2-dimethoxyethane with tert-butylamine, crystallization; stereospecific | REN, AGTR2, AGTR1 | ACE 8/4885KMT2A 960/4885MEN1 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.